• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

1.760 -0.170 (-8.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 66,148
Open 1.940
Bid (Size) 1.750 (100)
Ask (Size) 2.020 (200)
Prev. Close 1.930
Today's Range 1.719 - 1.940
52wk Range 0.9700 - 3.265
Shares Outstanding 5,564,315
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Top stock movements in today's session. ↗
February 19, 2026
Via Chartmill
Gapping stocks in Thursday's session ↗
February 19, 2026
Via Chartmill

Performance

YTD
+32.3%
+32.3%
1 Month
+15.0%
+15.0%
3 Month
+50.4%
+50.4%
6 Month
-6.4%
-6.4%
1 Year
-30.4%
-30.4%

More News

Read More
Stay updated with the stocks that are on the move in today's pre-market session. ↗
February 19, 2026
Via Chartmill
News headline image
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
February 19, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
TRAW Stock Slides In Volatile Session –  What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗
January 26, 2026
Via Stocktwits
Top movers analysis in the middle of the day on 2026-01-28: top gainers and losers in today's session. ↗
January 28, 2026
Via Chartmill
News headline image
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
January 26, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
January 13, 2026
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
December 17, 2025
Via Chartmill
News headline image
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
December 17, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
November 14, 2025
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
November 14, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
November 14, 2025
Via Benzinga
News headline image
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
November 13, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
October 27, 2025
Via Benzinga
News headline image
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
October 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
October 06, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
Via Investor Brand Network
News headline image
Annovis Appoints Mark Guerin as Chief Financial Officer
September 25, 2025
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
September 17, 2025
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
September 05, 2025
Via Benzinga
News headline image
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
August 18, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
August 14, 2025
Via Benzinga
News headline image
Traws Pharma Posts Q2 Revenue Jump ↗
August 14, 2025
Via The Motley Fool
News headline image
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
August 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Traws Pharma, Inc. - Common Stock publicly traded?
Yes, Traws Pharma, Inc. - Common Stock is publicly traded.
What exchange does Traws Pharma, Inc. - Common Stock trade on?
Traws Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Traws Pharma, Inc. - Common Stock?
The ticker symbol for Traws Pharma, Inc. - Common Stock is TRAW on the Nasdaq Stock Market
What is the current price of Traws Pharma, Inc. - Common Stock?
The current price of Traws Pharma, Inc. - Common Stock is 1.760
When was Traws Pharma, Inc. - Common Stock last traded?
The last trade of Traws Pharma, Inc. - Common Stock was at 03/27/26 04:00 PM ET
What is the market capitalization of Traws Pharma, Inc. - Common Stock?
The market capitalization of Traws Pharma, Inc. - Common Stock is 9.79M
How many shares of Traws Pharma, Inc. - Common Stock are outstanding?
Traws Pharma, Inc. - Common Stock has 10M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap